Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor

Evaluation committee members

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D.

Committee members are asked to declare any interests in the technology being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

The minutes of each evaluation committee meeting, which include the names of the members who attended and their declarations of interests, are posted on the NICE website.

Chairs

Megan John and Amanda Adler
Chair and interim vice chair, technology appraisal committee D

NICE project team

Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the evaluation), a technical adviser, a project manager and an associate director.

Tom Palmer
Technical lead

Alex Sampson
Technical adviser

Kate Moore
Project manager

Ian Watson and Lorna Dunning
Associate directors

ISBN: 978-1-4731-7257-9